Carbamic Acid

Carbamic Acid

SCHEMBL1861901

NC(=O)O.O=[N+]([O-])c1n[nH]c2ccccc12

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.45
STAT3 P40763 1/20 0.45
HIF1A Q16665 1/20 0.45
GAA P10253 3/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
PDPK1 O15530 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAP2K4 P45985 2/20 0.44
CDK2 P24941 3/20 0.43
CCNA2 P20248 1/20 0.43
FLT3 P36888 1/20 0.43
CCNA1 P78396 1/20 0.43
ALDH1A1 P00352 4/20 0.43
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
IDO1 P14902 2/20 0.42
ALPL P05186 1/20 0.42
TTK P33981 1/20 0.42
MAPK10 P53779 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30071547 0.90 KDM4E (0.48) KDM4ESTAT3HIF1AGAAMAPT
SCHEMBL342380 0.90 KDM4E (0.48) KDM4ESTAT3HIF1AGAAMAPT
Hydrochloric Acid SCHEMBL28220934 0.89 KDM4E (0.47) KDM4ESTAT3HIF1AGAAMAPT
SCHEMBL8988307 0.77 MAPT (0.41) KDM4ESTAT3HIF1AGAAMAPT
Carbamic Acid SCHEMBL1857015 0.76 KDM4E (0.77) KDM4ESTAT3HIF1AGAAHPGD
SCHEMBL9493092 0.75 FGFR1 (0.46) KDM4ESTAT3HIF1AGAAMAPT
SCHEMBL924277 0.74 LMNA (0.46) MAP2K4MAPK1MAPKAPK3MAPK6TP53
SCHEMBL4056717 0.71 AR (0.54) KDM4EGAAMAPTALDH1A1MEN1
Bicarbonate SCHEMBL1573525 0.71 KDM4E (0.80) KDM4ESTAT3HIF1AGAAHPGD
Urea SCHEMBL2190330 0.71 KDM4E (0.80) KDM4ESTAT3HIF1AGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487116-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. (US) 2013-07-16 US disclosed
CN-102617464-A fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor ABBOTT LAB 2012-08-01 CN disclosed
US-20120190845-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBVIE INC. 2012-07-26 US disclosed
US-8071762-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LABORATORIES (US) 2011-12-06 US disclosed
EP-2017265-B1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2011-05-25 EP disclosed
CN-101445501-A Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2009-06-03 CN disclosed
EP-2017265-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor Abbott Laboratories (US) 2009-01-21 EP disclosed
US-20080287676-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2008-11-20 US disclosed
EP-1658269-B1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LAB (US) 2008-10-22 EP disclosed
US-7375126-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LABORATORIES (US) 2008-05-20 US disclosed
CN-1835924-A Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor ABBOTT LAB (US) 2006-09-20 CN disclosed
EP-1658269-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR Abbott Laboratories (US) 2006-05-24 EP disclosed
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. 2005-02-24 US disclosed
WO-2004111009-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287676-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ARRB1, TRPV1, TRPV5 KDM4E 3505/4885STAT3 2235/4885HIF1A 1672/4885
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ARRB1, TRPV1, TRPV5 KDM4E 3329/4885STAT3 2092/4885HIF1A 1641/4885
US-20120190845-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ARRB1, TRPV1, TRPV5 KDM4E 3505/4885STAT3 2235/4885HIF1A 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.